Quanterix (NASDAQ:QTRX) agrees to acquire privately held Uman Diagnostics for $22.5M, comprised of $16M in cash and $6.5M in Quanterix shares
Uman possess antibodies to measure neurofilament light (Nf-L), and the acquisition positions Quanterix to capitalize opportunities with Nf-L applications in Alzheimer’s Disease, Multiple Sclerosis, and other neuro-degenerative conditions
The transaction is expected to provide 200 bps of annualized company gross margin improvement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.